


A Quick Look at Using Meningococcal Conjugate Vaccine (MCV4)

<p>MCV4 (meningococcal conjugate vaccine; Menactra™)</p> <p>Indications for Use and Schedule</p> <ul style="list-style-type: none"> · Routinely administer 1 dose to: <ul style="list-style-type: none"> - All adolescents at age 11-12 years - Any adolescent, 13-18 years of age, who has not previously received a dose · Recommended for persons 2-55 years of age at high risk* for meningococcal disease <p>Revaccination</p> <ul style="list-style-type: none"> · Revaccinate certain high risk persons who previously received MCV4 and remain at high risk**. Intervals between doses are: <ul style="list-style-type: none"> - 3 years for children ages 2- 6 years - 5 years for persons ages 7 years and older 	<p>Vaccine Administration</p> <ul style="list-style-type: none"> · Intramuscular (IM) injection in the deltoid of the arm · 1-1.5 inch needle; 22-25 gauge · Professional judgment is appropriate when selecting needle length and site · Can be given simultaneously with other vaccines <p>Storage and Handling</p> <ul style="list-style-type: none"> · Store in the refrigerator between 35°-46° F (2°-8°C) · Do NOT freeze · Keep in the original box · Shake well before using 
--	--

*HIGH RISK CONDITIONS/GROUPS

- College freshmen, living in dormitories
- Persons with functional or anatomic asplenia, HIV or terminal complement component deficiency
- Travelers or residents of countries where meningococcal disease is common, such as parts of Africa
- Persons who may have been exposed to meningitis during an outbreak (except serogroup B outbreaks--not in the vaccine)
- Military recruits
- Lab personnel working with these organisms

** REVACCINATE PERSONS WITH THESE HIGH RISK CONDITIONS

- Persons with functional or anatomic asplenia, HIV or terminal complement component deficiency
- Travelers or residents of countries where meningococcal disease is common, such as parts of Africa

CONTRAINDICATIONS

- An anaphylactic reaction to a prior dose of MCV4 vaccine
- An anaphylactic reaction to a component of MCV4 vaccine
- A history of Guillain-Barré Syndrome (use MPSV4- meningococcal polysaccharide vaccine [Menomune®]) if vaccination is recommended)

PRECAUTIONS

- Moderate to severe acute illness

FURTHER POINTS

- MCV4 and Td/Tdap may cause larger local reactions than other vaccines such as Hep B or Var. If indicated, administer these two vaccines at the same visit, but consider using separate limbs such as opposite arms
- Due to increased reports of syncope (fainting) in adolescents following vaccination, a 15 minute waiting period is recommended for adolescents after receiving vaccines
- MCV4 contains serotypes A, C, Y, and W-135. Serotype B is not in either vaccine
- Meningococcal Vaccine Information Statement (VIS), including information about the Michigan Care Improvement Registry (MCIR), can be found at www.michigan.gov/immunize or your local health department
- Document as "menin conj MCV4" in MCIR and as "MCV4" on the vaccine administration record & immunization record card

Publicly purchased MCV4 (Menactra) can be administered to eligible children 2 through 18 years of age with an indication for vaccination through the Vaccines for Children (VFC) Program in private providers' offices. Eligible children include those who are uninsured, underinsured, Medicaid eligible, Native American or Alaskan Natives. Contact your local health department for more information

For additional information, refer to VFC Program Resolutions and ACIP Recommendations on Vaccines to Prevent Meningococcal Disease, located at <http://www.cdc.gov/vaccines/recs>

July 14, 2009